CAMBRIDGE, Mass., July 5, 2023 /PRNewswire/ — Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective July 1, 2023, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 13,093 shares…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.